Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P
Applied Genetics Incorporated Dermatics, Freeport, NY 11520, USA.
Lancet. 2001 Mar 24;357(9260):926-9. doi: 10.1016/s0140-6736(00)04214-8.
In patients with xeroderma pigmentosum the frequency of all forms of skin cancer is higher than in the general population, owing to a genetic defect in DNA repair. The bacterial DNA repair enzyme, T4 endonuclease V, delivered intracellularly, increases the rate of repair of sunlight-induced DNA damage in human cells. We tested the ability of this enzyme in a liposomal delivery vehicle applied topically (T4N5 liposome lotion) to lower the rate of new skin cancers in patients with xeroderma pigmentosum.
30 patients were enrolled in this prospective, multicentre, double-blind study. Patients were randomly assigned T4N5 liposome lotion or a placebo liposome lotion, to be applied daily for 1 year. At 3-monthly visits, new actinic keratoses and basal-cell carcinomas were identified and removed. Analyses were by intention to treat.
20 patients were assigned T4N5 liposome lotion and ten placebo lotion; one placebo-group patient withdrew before treatment and one withdrew with progressive disease at 9 months. The annualised rate of new actinic keratoses was 8.2 among the patients assigned T4N5 liposome lotion and 25.9 among those assigned placebo (difference 17.7 [95% CI 11.8-26.5]; p=0.004 by Poisson modelling). For basal-cell carcinoma, the annualised rates of new lesions were 3.8 in the treatment group and 5.4 in the placebo group (difference 1.6 [0.38-2.82]). No significant adverse effects were found among any of the patients.
DNA damage has an important role in the development of skin cancer and precancerous skin lesions. The topical application of DNA repair enzymes to sun-damaged skin of patients with xeroderma pigmentosum lowered the rate of development of two forms of these lesions during a year of treatment.
由于DNA修复存在遗传缺陷,着色性干皮病患者患各类皮肤癌的频率高于普通人群。经细胞内递送的细菌DNA修复酶T4核酸内切酶V,可提高人体细胞中阳光诱导的DNA损伤的修复速率。我们测试了这种酶以脂质体递送载体局部应用(T4N5脂质体洗剂)时,降低着色性干皮病患者新发皮肤癌发生率的能力。
30名患者参与了这项前瞻性、多中心、双盲研究。患者被随机分配使用T4N5脂质体洗剂或安慰剂脂质体洗剂,每日应用,持续1年。每3个月复诊时,识别并切除新发的光化性角化病和基底细胞癌。分析采用意向性治疗。
20名患者被分配使用T4N5脂质体洗剂,10名使用安慰剂洗剂;1名安慰剂组患者在治疗前退出,1名在9个月时因病情进展退出。分配使用T4N5脂质体洗剂的患者中,光化性角化病的年化发生率为8.2,而分配使用安慰剂的患者中为25.9(差异17.7 [95%可信区间11.8 - 26.5];通过泊松模型分析,p = 0.004)。对于基底细胞癌,治疗组新发病变的年化发生率为3.8,安慰剂组为5.4(差异1.6 [0.38 - 2.82])。未在任何患者中发现显著的不良反应。
DNA损伤在皮肤癌和癌前皮肤病变的发生中起重要作用。在一年的治疗期间,将DNA修复酶局部应用于着色性干皮病患者受阳光损伤的皮肤,可降低这两种病变的发生率。